Objective: Myeloid/lymphoid neoplasms with fibroblast growth factor receptor-1 (FGFR1)
rearrangement are hematopoietic stem cell disorders with a poor prognosis, but no …

Allogeneic hematopoietic cell transplantation (allo-HCT) is the only curative treatment for
patients with myeloid/lymphoid neoplasm (MLN) with FGFR1 rearrangement, but data on …

Myeloid/lymphoid neoplasms with FGFR1 rearrangement are a rare entity. We present a
multicenter experience of 17 patients with FISH-confirmed FGFR1 rearrangement. The …

Objectives: Myeloid and lymphoid neoplasms with abnormalities of fibroblast growth factor
receptor 1 gene (FGFR1) are a rare and aggressive disease group that harbors …

PDGFRA, PDGFRB, FGFR1 and the PCM1-JAK2 rearrangement [1]. Among these, FGFR1
(Fibroblast Growth Factor Receptor 1; chromosome 8p11. 2) rearranged neoplasms result in …

Objectives This session of the 2013 Society for Hematopathology/European Association for
Haematopathology Workshop was dedicated to tumors currently included in the World …

(13q12), MYO18A (17q11), 17q25, HERVK (19q13), and BCR (22q11)[1, 3, 4]. Among
those, the most frequent partner gene is the ZMYM2 gene which resembles approximately …

Introduction Myeloid/lymphoid neoplasms with fibroblast growth factor receptor-1 (FGFR1)
rearrangements (MLNFGFR1) are rare entities with aggressive features and poor prognosis …

FGFR1 translocation may cause myeloid or lymphoid neoplasm but rarely systemic
mastocytosis (SM). Conversely, SM is associated with myeloproliferative neoplasm (MPN) …

Hematopoietic neoplasms with FGFR1 rearrangements are rare. Clinically, patients often
present with a chronic myeloproliferative neoplasm with eosinophilia and an increased risk …